AZN - AstraZeneca PLC - Stock Price & Dividends

Exchange: London Exchange • Country: United Kingdom • Currency: GBX • Type: Common Stock • ISIN: GB0009895292

Cancer, Respiratory, Cardiovascular, Diabetes, Infection, RareDisease

AstraZeneca PLC is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines to improve people's lives. With a focus on innovation, the company has developed a diverse portfolio of medicines that cater to various therapeutic areas, including cardiovascular, renal, metabolism, and oncology.

The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp, which are prescribed by primary care and specialty care physicians to treat a range of health conditions.

In addition to its core portfolio, AstraZeneca also offers a range of medicines for rare diseases and COVID-19, including Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma. The company's commitment to innovation and collaboration has led to partnerships like the one with Neurimmune AG to develop and commercialize NI006.

With a strong presence in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia, AstraZeneca serves its customers through a network of distributors and local representative offices. Founded in 1992 as Zeneca Group PLC, the company changed its name to AstraZeneca PLC in April 1999 and is headquartered in Cambridge, the United Kingdom. For more information, visit

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AZN - AstraZeneca PLC  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for AZN - AstraZeneca PLC  - Stock Price & Dividends

AZN Stock Overview

Market Cap in USD 2,435m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1993-05-12

AZN Stock Ratings

Growth 5y 71.4
Fundamental 50.9
Dividend 40.6
Rel. Performance vs Sector 0.92
Analysts -
Fair Price Momentum 12313.08 GBX
Fair Price DCF 98.38 GBX

AZN Dividends

Dividend Yield 12m 1.88%
Yield on Cost 5y 4.05%
Dividends CAGR 5y 1.41%
Payout Consistency 98.2%

AZN Growth Ratios

Growth 12m 15.44%
Growth Correlation 12m 30%
Growth Correlation 3m 16%
CAGR 5y 16.45%
CAGR/Mean DD 5y 2.07
Sharpe Ratio 12m 0.47
Alpha vs SP500 12m 5.43
Beta vs SP500 5y weekly 0.26
ValueRay RSI 36.37
Volatility GJR Garch 1y 20.53%
Price / SMA 50 -1.39%
Price / SMA 200 11.04%
Current Volume 957.8k
Average Volume 20d 1376.5k

External Links for AZN Stock

Fund Manager Positions
What is the price of AZN stocks?
As of July 20, 2024, the stock is trading at GBX 12106.00 with a total of 957,828 shares traded.
Over the past week, the price has changed by -1.26%, over one month by -1.90%, over three months by +10.60% and over the past year by +15.98%.
What are the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca PLC will be worth about 13373.2 in July 2025. The stock is currently trading at 12106.00. This means that the stock has a potential upside of +10.47%.
Issuer Forecast Upside
Wallstreet Target Price 130.3 -98.9
Analysts Target Price - -
ValueRay Target Price 13373.2 10.5

A Look into AstraZeneca PLC: From Origins to Global Pharma Leader

History of AstraZeneca

AstraZeneca, a global biopharmaceutical juggernaut, originated from the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group. Since its inception, AstraZeneca has focused on developing medications in oncology, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory diseases. This merger was not just a fusion of names but of vast research prowess and a rich portfolio of innovative medicines.

Core Business

AstraZeneca's core lies in discovering, developing, and commercializing prescription medicines. Primarily, their work revolves around three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology. In oncology, AstraZeneca has made significant strides, providing innovative treatments that have changed the lives of many patients. Their dedication to cardiovascular and metabolic diseases has also led to the development of leading medicines aimed at combating these conditions. Moreover, their respiratory portfolio is robust, addressing asthma and chronic obstructive pulmonary disease (COPD) among others.

Side Businesses and Collaborations

Beyond their primary focus, AstraZeneca engages in various other businesses, including the manufacturing of hospital and dental supplies. They’ve also established several strategic collaborations to bolster their research and development capabilities, partnering with academic institutions, biotechnology companies, and government entities. These collaborations aim to accelerate the delivery of innovative treatments to patients.

Current Market Status

As of the latest financial reports, AstraZeneca continues to show robust performance in the global market. Their strategic acquisitions and partnerships have expanded their pipeline and market presence significantly. Despite the challenges posed by global market fluctuations and the constantly evolving healthcare landscape, AstraZeneca has maintained a strong growth trajectory, thanks to their continuous innovation and the development of high-demand medications. The company's commitment to addressing unmet medical needs continues to drive its success, making it a formidable player in the pharmaceutical industry.